Envision Pharma Group’s Post

Patient groups feel they are making a significant impact with pharma manufacturers to improve the patient experience. The 'bottom-up' marketing strategy - starting with patient input and funneling up to decision-makers, is good business practice compared with conventional 'top-down' management that imposes terms on patient-consumers and contributes to distrust of the pharma industry. https://lnkd.in/grYTrAU3 #transparency #3PLpharma #logistics

Over the past few years, many #pharma companies have explored direct-to-patient platforms and delivery approaches. If your organization is considering going down this path, here are three questions to consider before you do so: 1️⃣ Is your product and/or therapeutic area the right fit for this service offering? 2️⃣ Build or buy – what are your key capabilities and where do you need help? 3️⃣ Quality, governance, and credibility – upon launch how will you be perceived? The move towards direct-to-patient can be a great way to increase accessibility, but it's crucial companies adopt this approach thoughtfully. Great insight from Jenna Phillips! #LifeSciences #Healthcare #FutureOfHealthcare

Article ✍🏻 | Integrate the patient perspective into your value strategy   The landscape of healthcare is constantly evolving. But today it’s all obvious that incorporating the patient’s perspective into value strategies has become essential.   Health agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are willing to approve treatments that the patient really needs. Healthcare agencies and, more generally, healthcare systems around the world want to provide care that is not only effective, but also patient centered.   📰 This article explores practical ways of integrating the patient perspective into value strategy, to ensure that future patient healthcare solutions are not only clinically effective, but also fully meet patients’ deepest needs.   Dive into our latest article: "How to integrate the patient perspective into your value strategy?" 🚀 Read now 👉 https://lnkd.in/efMVbSt6 #patientperspective #QoL #valuestrategy #patients

Let's discuss how to generate a Patient Centered Outcomes Research to enrich your value proposition - get the patient perspectives with robust methodologies

Today’s patients have evolved beyond mere medication. They want to actively participate in their #healthcarejourney, access all the information about the drug and its impact on their health conditions, and stay connected to their care providers for instant support. On the other hand, #pharmaceutical companies have also realized the care gap and started expanding Patient support programs (PSPs) to improve patient outcomes and foster loyalty. Such as - ~ Personalized digital solutions alongside the drug that help patients optimize their medication outcomes ~ Personalized in-person support services that cater to patients’ unique health conditions, ensuring convenient and timely access, utilization, and adherence. But how can Pharma further utilize #digitalhealthsolutions, such as patient or companion apps, to close the gap between patient needs and expectations? To find out more, check out our latest blog post: https://lnkd.in/dXzZtmEY #patientexperience #patientcentricity #patientsupport #newpagesolutions

🌟 Exploring the Complexities of STGs and Pharmacy & Therapeutics Committees 🌟 As professionals deeply engaged in healthcare, we understand that the pursuit of optimal patient care is a multifaceted journey. Today, I want to shine a light on the intricate realm of Standard Treatment Guidelines (STGs) and Pharmacy & Therapeutics (P&T) Committees – two pillars crucial to navigating the landscape of modern healthcare. STGs serve as blueprints, offering standardized protocols and procedures to guide healthcare providers in delivering evidence-based care. They streamline decision-making processes, ensuring consistency and quality across various healthcare settings. However, in their implementation, they often encounter a myriad of challenges. One such challenge lies in the dynamic nature of medical science. With advancements and discoveries occurring at a rapid pace, STGs must continually evolve to incorporate the latest evidence and best practices. Balancing the need for agility with the imperative of maintaining robust standards poses a perpetual challenge for healthcare systems worldwide. Moreover, the diversity of patient populations further complicates the formulation and application of STGs. What works effectively for one demographic or region may not necessarily yield the same outcomes elsewhere. Cultural, socioeconomic, and genetic factors all play pivotal roles, necessitating nuanced adaptations of treatment guidelines to ensure equitable and personalized care for all. Enter the Pharmacy & Therapeutics Committees – the guardians of medication management and therapeutic efficacy within healthcare institutions. Charged with the critical task of evaluating pharmaceutical products and formularies, these committees wield immense influence over patient outcomes. Yet, their deliberations often navigate through a labyrinth of considerations. From assessing drug efficacy and safety profiles to balancing cost-effectiveness and accessibility, P&T Committees face a delicate balancing act. The decisions they make ripple through the entire healthcare ecosystem, impacting treatment pathways, resource allocation, and ultimately, patient well-being. However, amidst these complexities lie boundless opportunities for collaboration, innovation, and advancement. By fostering interdisciplinary dialogue and leveraging technology and data-driven insights, we can navigate the intricacies of STGs and P&T Committees with greater efficacy and precision. As stakeholders committed to advancing healthcare excellence, let us embrace these challenges as catalysts for growth and transformation. Together, let us forge a future where STGs and P&T Committees serve as beacons of excellence, guiding us towards a world of healthier, happier communities. #Healthcare #STGs #PTCommittees #EvidenceBasedMedicine #PatientCare #Collaboration #Innovation

By leveraging data, clinical expertise, and digital tools, healthcare payers and pharmaceutical companies can collaborate to improve patient journeys and treatment management in value-based care for chronic diseases. A collaborative, VBC-oriented approach using virtual care models can personalize care delivery, optimize resource allocation, and ultimately improve patient outcomes. #ValueBasedCare #Healthcare #VBC

#Healthcare access and quality is one of the key areas of Social Determinants of Health (#SDOH), as defined by the World Health Organization. We at Avantpage Life Sciences and Avantpage Translations, our parent company, have been #language advocates for nearly three decades. We believe #translationservices help improve health and lives, in any language. Our clients from the #biopharmaceutical and #medicaldevices industry recognize that SDOH are pivotal factors influencing #patientoutcomes. SDOH data needs to be effectively integrated into #clinicaltrial recruitment to result in meaningful improvements in #patientcare. The key considerations for clinical trial diversity make a long list, which starts with one simple question: "What is the first language of my patients?". Determining your patient population and providing materials in the languages they need is the first step to ensuring thorough research and real-world evidence. https://lnkd.in/dFMsa6r7

🏥 How can data-driven insights optimize a patient care pathway and improve health outcomes? 📊   👩🏼⚕️ In a recent article by BioVox, Flemish experts from The Janssen Pharmaceutical Companies of Johnson & Johnson and imec share their thoughts on how decision support tools can help healthcare professionals, as well as making the difference in defining the care journey for the patient.   #Collaboration and #innovation are the key words to this approach, alongside listening to patients' needs and hints thanks to the patient-reported outcome measures (#PROMs), and not focusing attention only on the mere clinical and claims data.   Privacy related issues could at first cause an obstacle in this direction, but the aim of the joint initiative from VITO, imec, MEDVIA and #FlandersInnovationandEntrepreneurship - the #SaveData project - wants to provide a solution to this.   If you want to learn more about how data can transform healthcare, read the full article here: https://lnkd.in/em7j-8uy   Marleen Verstreken | Sophie Massagé | Flanders Investment & Trade - Italia David Smeets | Christel Meertens

🌍 Access to affordable medicines remains a critical global challenge. 🏥Discover how we are slowing shaping a future where healthcare equity is a reality for all. #HealthcareInnovation #AccessToMedicines #GlobalHealth 🌍💊 Despite advancements in technology and innovation, millions remain excluded from essential treatments. We explore various methods to expand access to medications, focusing on evidence-based policies, innovative strategies, and the power of collaboration. Key takeaways include the role of evidence and transparency in achieving 'fair prices', the need for innovative policy reform, and the importance of multi-sectoral collaboration for sustainable access to affordable medications. 🤝💪🏽 #PharmaceuticalPolicy #Collaboration #HealthEquity 🌍🩺💊 https://lnkd.in/gd4b-UuN